Sri Lanka’s Branded-Drug Ban Seen As Boon To India’s Generics (India)
This article was originally published in PharmAsia News
Sri Lanka's decision to ban prescriptions for branded drugs is viewed by India's generic-drugs industry as beneficial to its companies. A "trade source" said the move means India, as the leading country for generic drugs, will be the primary beneficiary. He noted that half of the drugs imported by Sri Lanka not only are made in India; nearly all Indian medicines are imported into the country. Sri Lanka's intention in ordering physicians to prescribe only generics was to force down the prices of drugs. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.